Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1-Reference-Cited by-同舟云学术

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1

Published:2024-06-14 Issue:12 Volume:67 Page:10306-10320
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sabat Mark¹,Carney Daniel W.¹^ORCID,Hernandez-Torres Gloria¹,Gibson Tony S.¹^ORCID,Balakrishna Deepika¹,Zou Hua¹,Xu Rui¹^ORCID,Chen Chien-Hung¹,de Jong Ron¹,Dougan Douglas R.¹,Qin Ling¹,Bigi-Botterill Simone V.¹^ORCID,Chambers Alison¹,Miura Joanne¹,Johnson Lucas K.¹^ORCID,Ermolieff Jacques¹,Johns Deidre¹,Selimkhanov Jangir¹,Kwok Lily¹^ORCID,DeMent Kevin¹^ORCID,Proffitt Chris¹,Vu Phong¹,Lindsey Erick A.¹,Ivetac Tony¹,Jennings Andy¹,Wang Haixia¹,Manam Padma¹,Santos Cipriano¹,Fullenwider Cody¹,Manohar Rohan¹,Flick Andrew C.¹^ORCID

Affiliation:

1. Gastroenterology Drug Discovery Unit, Takeda Development Center Americas, Inc., 9625 Towne Centre Dr., San Diego, California 92121 United States

Funder

Takeda Pharmaceutical Company

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00743

Reference40 articles.

1. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals

2. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

3. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

4. The global NAFLD epidemic

5. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress in visible light‐driven halogenation: Chlorination, bromination, and iodination;Bulletin of the Korean Chemical Society;2024-09-03